These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 23032961)

  • 1. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    You JH; Tsui KK; Wong RS; Cheng G
    PLoS One; 2012; 7(6):e39640. PubMed ID: 22745801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
    Carles M; Brosa M; Souto JC; Garcia-Alamino JM; Guyatt G; Alonso-Coello P
    BMC Health Serv Res; 2015 Jul; 15():289. PubMed ID: 26215871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Berg AM
    Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502659
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
    Messori A; Fadda V; Maratea D; Trippoli S
    J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):683-5. PubMed ID: 23032961
    [No Abstract]   [Full Text] [Related]  

  • 10. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
    Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
    Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
    Rahme RJ; Bernstein R; Batjer HH; Bendok BR
    Neurosurgery; 2011 Feb; 68(2):N16-7. PubMed ID: 21654569
    [No Abstract]   [Full Text] [Related]  

  • 12. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
    Faria R; Spackman E; Burch J; Corbacho B; Todd D; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2013 Jul; 31(7):551-62. PubMed ID: 23620211
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.